Skip to main content
. 2020 Jul;38(3):230–239. doi: 10.2337/cd19-0086

TABLE 4.

Completers Analysis

Control Group OR (CI) Intervention Group OR (CI)
Visit 1 (n = 91) Visit 2 (n = 91) Visit 3 (n = 91) Visit 1 (n = 67) Visit 2 (n = 67) Visit 3 (n = 67)
A1C, % 8.6 (0.2) 8.3 (0.2) 8.3 (0.2) NA 8.6 (0.2) 8.2 (0.2) 8.0 (0.2)*** NA
BMI, kg/m2 32.5 (0.7) 32.1 (0.7) 32.4 (0.7) NA 33.7 (0.8) 33.6 (0.8) 34.0 (0.8) NA
Blood pressure, mmHg
 Systolic 135.7 (2.2) 134.5 (2.2) 132.1 (2.2) NA 136.2 (2.5) 130.9 (2.5) 129.3 (2.5)* NA
 Diastolic 78.3 (1.0) 77.8 (1.0) 76.8 (1.0) NA 79.7 (1.1) 76.1 (1.1) 75.2 (1.1)** NA
PAID score 27.4 (2.5) 20.0 (2.5)** NA 28.1 (2.8) 19.8 (2.8)** NA
MMAS score 6.1 (0.2) 6.3 (0.2) 6.3 (0.2) NA 6.4 (0.2) 6.5 (0.2) 6.4 (0.2) NA
SCI-R score 56.1 (1.3) 56.8 (1.3) 59.2 (1.3)* NA 57.4 (1.5) 60.0 (1.5) 59.7 (1.5)* NA
Participate in physical activity, % 57.8 (0.05) 62.6 (0.05) 57.1 (0.05) 1.0 (0.6–1.8) 61.2 (0.06) 70.2 (0.06) 65.7 (0.06) 1.2 (0.4–1.6)
Exercise, hours/week 3.5 (0.4) 3.2 (0.4) 3.2 (0.4) NA 4.1 (0.4) 3.7 (0.4) 3.0 (0.4)* NA
Using insulin, % 57.8 (0.05) 58.9 (0.05) 61.1 (0.05) 0.9 (0.6–2.0) 55.2 (0.06) 59.1 (0.06) 56.7 (0.06) 1.1 (0.5–1.8)
Treatment regimen, %
 Lifestyle modification 4.4 (0.02) 3.3 (0.02) 1.1 (0.01) 4.1 (0.02–1.8) 4.5 (0.03) 4.5 (0.03) 4.5 (0.03) 1.0 (0.2–5.1)
 Oral medications 37.2 (0.05) 38.1 (0.05) 36 (0.05) 1.1 (0.5–1.7) 39.1 (0.06) 37.7 (0.06) 39.1 (0.06) 1.0 (0.5–2.0)

Data from each visit are mean (SE). *P <0.05 compared to baseline. **P <0.001 compared to baseline. ***P <0.0001 compared to baseline. NA, not applicable.